Medtech companies are increasingly investing in neuromodulation to treat UUI, which is estimated to impact 20% of adults worldwide.

The neuromodulation devices market is expanding swiftly, propelled by the increasing global incidence of chronic conditions such as pain, epilepsy, and depression. This growth is further supported by ...

ReShape Lifesciences has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application on a new Diabetes Neuromodulation system utilizing its vagal nerve block ...

Key findings included 94% of test-phase responders experienced at least a 50% decrease in episodes of UUI.

Patients who receive an Altaviva device return home with therapy activated. Medtronic says this marks a first among ...

Theranica, a neuromodulation therapeutics company advancing clinically validated, drug-free treatments for idiopathic pain conditions and setting a new standard of care in migraine with REN-based ...

ReShape Lifesciences® announced the presentation of pre-clinical data for its innovative Diabetes Neuromodulation device at the Minnesota Neuromodulation Symposium. This device employs Hypoglycemia ...

Given the growing interest in non-invasive neuromodulation devices for the central nervous system, the Forum on Neuroscience and Nervous System Disorders hosted a public workshop on March 2-3, 2015 to ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Neuromodulation offers personalized, responsive ...